46.50 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||32.53 x 800|
|Ask||47.50 x 1200|
|Day's Range||44.52 - 46.72|
|52 Week Range||29.57 - 50.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.00|
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).
Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD). “We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Shares of Celgene (CELG) and Acceleron Pharma (XLRN) are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. Acceleron is up 2.3% to $48.50, while Celgene is climbing 0.9% to $84.60.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...
Inc. reported positive results from a trial of their drug Luspatercept, a drug to treat chronic anemia, beta-thalassemia and myelofibrosis. The results announced Monday, the companies said, reflect testing on beta-thalassemia patients who are dependent on blood transfusions. Patients showed at least a one-third reduction in dependence on transfusions, the companies said.
MARKET PULSE Celgene Corp. (celg) and Acceleron Pharma Inc. (xlrn) shares pushed higher in the extended session Monday after the biotech companies said a clinical trial showed their jointly developed drug was effective in treating a certain type of inherited blood disorder.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 percent reduction from baseline in red blood cell (RBC) transfusion burden with a reduction of at least 2 units during the protocol-defined period of 12 consecutive weeks, from week 13 to week 24, compared to placebo. BELIEVE evaluated the efficacy and safety of luspatercept plus best supportive care versus placebo plus best supportive care in adults with transfusion-dependent beta-thalassemia.
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablynx NV. “Robert has built an impressive career, holding a variety of leadership positions across clinical development, regulatory, and medical affairs functions,” said Habib Dable, Chief Executive Officer of Acceleron.
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Acceleron Pharma and Vertex Pharmaceuticals both saw big gains on Friday on separate positive catalysts last week. Acceleron and Celgene reported strong results ...
Acceleron Pharma shares rocketed early Friday after it and Celgene reported strong results for a partnered anemia treatment called luspatercept.
Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal. Acceleron said that the drug reported a significant reduction in the need for blood transfusions in patients with MDS (myelodysplastic syndrome). CELG and XLRN stocks rose ~4% and 42%, respectively.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.
Acceleron Pharma Inc (NASDAQ: XLRN ), a clinical-stage biopharmaceutical focused on the treatment of serious and rare diseases, saw its stock soar after reporting encouraging Phase 3 data . But investors ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo. MEDALIST evaluated the efficacy and safety of luspatercept versus placebo in patients with IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) with chronic anemia and refractory to, intolerant of, or ineligible for treatment with an erythropoietin-stimulating agent (ESA), ring sideroblast-positive and require frequent RBC transfusions.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from the ongoing Phase 2 trial in patients with Charcot-Marie-Tooth (CMT) disease at the Peripheral Nerve Society (PNS) annual meeting held in Baltimore, Maryland, July 22-25, 2018. Part 1 is an open-label, dose-escalation study, with ACE-083 administered by injection into the TA muscle once every 3 weeks in up to 18 patients to evaluate safety and increases in muscle volume over a 3-month treatment period.
NEW YORK, June 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RCI ...
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in patients with beta-thalassemia during an oral presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene. “These results reinforce our enthusiasm for luspatercept’s potential as a safe, efficacious therapy for beta-thalassemia patients over the long term,” said Habib Dable, President and Chief Executive Officer of Acceleron.